share_log

Truist Securities Reiterates Buy on Cytokinetics, Maintains $86 Price Target

Truist Securities Reiterates Buy on Cytokinetics, Maintains $86 Price Target

Truist Securities重申对Cytokinetics的买入,维持86美元的目标股价
Moomoo 24/7 ·  04/08 11:07

Truist Securities analyst Srikripa Devarakonda reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $86 price target.

Truist Securities分析师Srikripa Devarakonda重申了Cytokinetics(纳斯达克股票代码:CYTK)的买入并维持86美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发